65 related articles for article (PubMed ID: 7479205)
1. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
Ko HC; Jusko WJ
Pharmacotherapy; 1995; 15(4):509-11. PubMed ID: 7479205
[TBL] [Abstract][Full Text] [Related]
2. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
[TBL] [Abstract][Full Text] [Related]
4. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
5. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
6. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
Kolasa A
Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
10. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.
Dallob AL; Sadick NS; Unger W; Lipert S; Geissler LA; Gregoire SL; Nguyen HH; Moore EC; Tanaka WK
J Clin Endocrinol Metab; 1994 Sep; 79(3):703-6. PubMed ID: 8077349
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
12. [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats].
Jia Y; Cue YG; Wang XD; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS
Zhonghua Nan Ke Xue; 2005 Jan; 11(1):38-41. PubMed ID: 15704680
[TBL] [Abstract][Full Text] [Related]
13. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol.
Reddy DS
Neuroscience; 2004; 129(1):195-207. PubMed ID: 15489042
[TBL] [Abstract][Full Text] [Related]
14. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
15. Fungi test for evaluation of new antiandrogenic molecule.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
[TBL] [Abstract][Full Text] [Related]
16. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
Bramson HN; Hermann D; Batchelor KW; Lee FW; James MK; Frye SV
J Pharmacol Exp Ther; 1997 Sep; 282(3):1496-502. PubMed ID: 9316864
[TBL] [Abstract][Full Text] [Related]
17. Effects of the anti-androgen finasteride on the modulatory actions of oestradiol on androgen metabolism by human gingival fibroblasts.
Tilakaratne A; Soory M
Arch Oral Biol; 2001 Feb; 46(2):109-15. PubMed ID: 11163318
[TBL] [Abstract][Full Text] [Related]
18. Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs.
Kamolpatana K; Johnston SD; Hardy SK; Castner S
Am J Vet Res; 1998 Jun; 59(6):762-4. PubMed ID: 9622748
[TBL] [Abstract][Full Text] [Related]
19. Effect of finasteride on human testicular steroidogenesis.
Castro-Magana M; Angulo M; Fuentes B; Canas A; Sarrantonio M; Arguello R; Vitollo P
J Androl; 1996; 17(5):516-21. PubMed ID: 8957695
[TBL] [Abstract][Full Text] [Related]
20. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
